Product Code: GVR-1-68038-375-1
CRISPR And Cas Genes Market Growth & Trends:
The global CRISPR and Cas genes market size is expected to reach USD 9.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 17.9% during the forecast period, owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.
The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher's emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.
Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.
It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company's CRISPR genes-driven diagnostics portfolio.
CRISPR And Cas Genes Market Report Highlights:
- By product and services, the product segment dominated the industry in 2021 due to the availability of a broad range of product portfolios & rising adoption by various end-users
- The biomedical segment dominated the industry in 2021. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth
- The biotechnology & pharmaceutical companies end-use segment captured the major revenue share in 2021. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification
- North America captured the highest revenue share in 2021 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Regional Scope
- 1.1.2 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis (Model 1)
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.7 Research Assumptions
- 1.8 Market Share Calculations
- 1.9 List Of Secondary Sources
- 1.10 List Of Abbreviations
- 1.11 Objectives
- 1.11.1 Objective 1
- 1.11.2 Objective 2
- 1.11.3 Objective 3
- 1.11.4 Objective 4
Chapter 2 Executive Summary
Chapter 3 Crispr & Cas Genes Market Variables, Trends And Scope
- 3.1 Market Segmentation & Scope
- 3.2 Market Driver Analysis
- 3.2.1 Growing Need For Novel Therapeutics
- 3.2.2 Rising Demand For Gene Editing
- 3.3.3 Rising Incidence Of Cancer
- 3.3 Market Restraint Analysis
- 3.3.1 Off-Target Effects Of Crispr Technology
- 3.3.2 High-Cost Factor, Intellectual Property Disputes & Ethical Dilemma
- 3.4 Crispr & Cas Genes Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
- 3.5 Industry Analysis - Porter's
Chapter 4 Product & Service Business Analysis
- 4.1 Crispr And Cas Genes Market: Product & Service Movement Analysis
- 4.1.1 By Product
- 4.1.1.1 Global Crispr And Cas Genes Products Market, 2018 - 2030 (USD Million)
- 4.1.1.2 Kits & Enzymes
- 4.1.1.2.1 Global Crispr And Cas Genes Kits And Enzymes Market, 2018 - 2030 (USD Million)
- 4.1.1.2.2 Vector-Based Cas9
- 4.1.1.2.2.1 Global Vector-Based Crispr And Cas Genes Market, 2018 - 2030 (USD Million)
- 4.1.1.2.3 Dna-Free Cas9
- 4.1.1.2.3.1 Global Dna-Free Crispr And Cas Genes Market, 2018 - 2030 (USD Million)
- 4.1.1.3 Libraries
- 4.1.1.3.1 Global Crispr And Cas Genes Libraries Market, 2018 - 2030 (USD Million)
- 4.1.1.4 Design Tools
- 4.1.1.4.1 Global Crispr And Cas Genes Design Tool Market, 2018 - 2030 (USD Million)
- 4.1.1.5 Antibodies
- 4.1.1.5.1 Global Crispr And Cas Genes Antibodies Market, 2018 - 2030 (USD Million)
- 4.1.1.6 Others
- 4.1.1.6.1 Global Crispr And Cas Genes Market For Others, 2018 - 2030 (USD Million)
- 4.1.2 By Service
- 4.1.2.1 Global Crispr And Cas Genes Service Market, 2018 - 2030 (USD Million)
- 4.1.2.2 Cell Line Engineering
- 4.1.2.2.1 Global Cell Engineering Services Market, 2018 - 2030 (USD Million)
- 4.1.2.3 gRNA Design
- 4.1.2.3.1 Global gRNA Design Market, 2018 - 2030 (USD Million)
- 4.1.2.4 Microbial Gene Editing
- 4.1.2.4.1 Global Microbial Gene Editing Market, 2018 - 2030 (USD Million)
- 4.1.2.5 Dna Synthesis
- 4.1.2.5.1 Global Dna Synthesis Market, 2018 - 2030 (USD Million)
Chapter 5 Application Business Analysis
- 5.1 Crispr And Cas Genes Market: Application Movement Analysis
- 5.1.1 Biomedical
- 5.1.1.1 Global Crispr And Cas Genes Market For Biomedical, 2018 - 2030 (USD Million)
- 5.1.1.2 Genome Engineering
- 5.1.1.2.1 Global Crispr And Cas Genes Market For Genome Engineering, 2018 - 2030 (USD Million)
- 5.1.1.3 Disease Model Studies
- 5.1.1.3.1 Global Crispr And Cas Genes Market For Disease Model Studies, 2018 - 2030 (USD Million)
- 5.1.1.4 Functional Genomics
- 5.1.1.4.1 Global Crispr And Cas Genes Market For Functional Genomics, 2018 - 2030 (USD Million)
- 5.1.1.5 Epigenetics
- 5.1.1.5.1 Global Crispr And Cas Genes Market For Epigenetics, 2018 - 2030 (USD Million)
- 5.1.1.6 Others
- 5.1.1.6.1 Global Crispr And Cas Genes Market For Others, 2018 - 2030 (USD Million)
- 5.1.2 Agriculture
- 5.1.2.1 Global Crispr And Cas Genes Market For Agriculture, 2018 - 2030 (USD Million)
Chapter 6 End-Use Business Analysis
- 6.1 Crispr And Cas Genes Market: End-Use Movement Analysis
- 6.1.1 Biotechnology & Pharmaceutical Companies
- 6.1.1.1 Global Crispr And Cas Genes Market For Biotechnology & Pharmaceutical Companies, 2018 - 2030 (USD Million)
- 6.1.2 Academics & Government Research Institutes
- 6.1.2.1 Global Crispr And Cas Genes Market For Academics & Government Research Institutes, 2018 - 2030 (USD Million)
- 6.1.3 Contract Research Organizations (Cros)
- 6.1.3.1 Global Crispr And Cas Genes Market For Contract Research Organizations (Cros), 2018 - 2030 (USD Million)
Chapter 7 Market Categorization: Regional Estimates & Trend Analysis by Product, Application & End-use
- 7.1 Regional Market Snapshot
- 7.2 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- 7.2.1 North America
- 7.2.2 Europe
- 7.2.3 Asia Pacific
- 7.2.4 Latin America
- 7.2.5 Middle East And Africa
- 7.3 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
- 7.4 North America
- 7.4.1 North America CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
- 7.4.2 U.S.
- 7.4.2.1 U.S. CRISPR & Cas Gene Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3 Canada
- 7.4.3.1 Canada CRISPR & Cas Genes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
- 7.5 Europe
- 7.5.1 Europe CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
- 7.5.2 Germany
- 7.5.2.1 Germany CRISPR & Cas Gene Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
- 7.5.3 U.K.
- 7.5.3.1 U.K. CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.5.4 France
- 7.5.4.1 France CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.5.5 Italy
- 7.5.5.1 Italy CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.5.6 Spain
- 7.5.6.1 Spain CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.6 Asia Pacific
- 7.6.1 Asia Pacific CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
- 7.6.2 Japan
- 7.6.2.1 Japan CRISPR & Cas Genes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3 China
- 7.6.3.1 China CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.6.4 South Korea
- 7.6.4.1 South Korea CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.6.5 India
- 7.6.5.1 India CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.7 Latin America
- 7.7.1 Latin America CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.7.2 Brazil
- 7.7.2.1 Brazil CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.7.3 Mexico
- 7.7.3.1 Mexico CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.8 Middle East & Africa (Mea)
- 7.8.1 MEA CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.8.2 South Africa
- 7.8.2.1 South Africa CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.8.3 Saudi Arabia
- 7.8.3.1 Saudi Arabia CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
- 8.1 Top CRISPR Innovators and Their Research Focus
- 8.2 Strategy Framework
- 8.3 Market Participant Categorization
- 8.4 Company Profiles
- 8.4.1 CARIBOU BIOSCIENCES
- 8.4.1.1 Company Overview
- 8.4.1.2 Financial Performance
- 8.4.1.3 Product Benchmarking
- 8.4.1.4 Strategic Initiatives
- 8.4.2 ASTRAZENECA
- 8.4.2.1 Company Overview
- 8.4.2.2 Financial Performance
- 8.4.2.3 Product Benchmarking
- 8.4.2.4 Strategic Initiatives
- 8.4.3 INTELLIA THERAPEUTICS, INC.
- 8.4.3.1 Company Overview
- 8.4.3.2 Financial Performance
- 8.4.3.3 Product Benchmarking
- 8.4.3.4 Strategic Initiatives
- 8.4.4 ADDGENE
- 8.4.4.1 Company Overview
- 8.4.4.2 Financial Performance
- 8.4.4.3 Product Benchmarking
- 8.4.5 CRISPR THERAPEUTICS
- 8.4.5.1 Company Overview
- 8.4.5.2 Financial Performance
- 8.4.5.3 Product Benchmarking
- 8.4.5.4 Strategic Initiatives
- 8.4.6 NEW ENGLAND BIOLABS
- 8.4.6.1 Company Overview
- 8.4.6.2 Financial Performance
- 8.4.6.3 Product Benchmarking
- 8.4.6.4 Strategic Initiatives
- 8.4.7 THERMO FISHER SCIENTIFIC, INC.
- 8.4.7.1 Company Overview
- 8.4.7.2 Financial Performance
- 8.4.7.3 Product Benchmarking
- 8.4.7.4 Strategic Initiatives
- 8.4.8 SYNTHEGO
- 8.4.8.1 Company Overview
- 8.4.8.2 Financial Performance
- 8.4.8.3 Product Benchmarking
- 8.4.8.4 Strategic Initiatives
- 8.4.9 MAMMOTH BIOSCIENCES
- 8.4.9.1 Company Overview
- 8.4.9.2 Financial Performance
- 8.4.9.3 Product Benchmarking
- 8.4.9.4 Strategic Initiatives
- 8.4.10 INSCRIPTA, INC.
- 8.4.10.1 Company Overview
- 8.4.10.2 Financial Performance
- 8.4.10.3 Product Benchmarking
- 8.4.10.4 Strategic Initiatives
- 8.4.11 CIBUS
- 8.4.11.1 Company Overview
- 8.4.11.2 Financial Performance
- 8.4.11.3 Product Benchmarking
- 8.4.11.4 Strategic Initiatives
- 8.4.12 BEAM THERAPEUTICS
- 8.4.12.1 Company Overview
- 8.4.12.2 Financial Performance
- 8.4.12.3 Product Benchmarking
- 8.4.12.4 Strategic Initiatives
- 8.4.13 PLANTEDIT
- 8.4.13.1 Company Overview
- 8.4.13.2 Product Benchmarking
- 8.4.14 VERTEX PHARMACEUTICALS INCORPORATED
- 8.4.14.1 Company Overview
- 8.4.14.2 Financial Performance
- 8.4.14.3 Product Benchmarking
- 8.4.14.4 Strategic Initiatives
- 8.4.15 GENSCRIPT
- 8.4.15.1 Company Overview
- 8.4.15.2 Financial Performance
- 8.4.15.3 Product Benchmarking
- 8.4.15.4 Strategic Initiatives
- 8.4.16 INTEGRATED DNA TECHNOLOGIES
- 8.4.16.1 Company Overview
- 8.4.16.2 Financial Performance
- 8.4.16.3 Product Benchmarking
- 8.4.16.4 Strategic Initiatives
- 8.4.17 LONZA
- 8.4.17.1 Company Overview
- 8.4.17.2 Financial Performance
- 8.4.17.3 Product Benchmarking
- 8.4.17.4 Strategic Initiatives
- 8.4.18 MERCK
- 8.4.18.1 Company Overview
- 8.4.18.2 Financial Performance
- 8.4.18.3 Product Benchmarking
- 8.4.18.4 Strategic Initiatives
- 8.4.19 HERA BIOLABS
- 8.4.19.1 Company Overview
- 8.4.19.2 Product Benchmarking
- 8.4.19.3 Strategic Initiatives
- 8.4.20 ORIGENE TECHNOLOGIES, INC.
- 8.4.20.1 Company Overview
- 8.4.20.2 Financial Performance
- 8.4.20.3 Product Benchmarking
- 8.4.21 RECOMBINETICS, INC.
- 8.4.21.1 Company Overview
- 8.4.21.2 Financial Performance
- 8.4.21.3 Product Benchmarking
- 8.4.21.4 Strategic Initiative